News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Sujata Varadharajan, MS

Articles by Sujata Varadharajan, MS

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Latest Updated Articles

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Published: July 15th 2005 | Updated:

Trending on AJMC

FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma

Guidelines for Bronchiectasis Highlight Multiple Treatment Methods

Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability

Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy

Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.